The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society

被引：580

作者：

Vlachopoulos, Charalambos ^{[1
]}

Xaplanteris, Panagiotis ^{[1
]}

Aboyans, Victor ^{[2
]}

Brodmann, Marianne ^{[3
]}

Cifkova, Renata ^{[4
]}

Cosentino, Francesco ^{[5
]}

De Carlo, Marco ^{[6
]}

Gallino, Augusto ^{[7
]}

Landmesser, Ulf ^{[8
]}

Laurent, Stephane ^{[9
,10
]}

Lekakis, John ^{[11
]}

Mikhailidis, Dimitri P. ^{[12
]}

Naka, Katerina K. ^{[13
]}

Protogerou, Athanasios D. ^{[14
,15
]}

Rizzoni, Damiano ^{[16
]}

Schmidt-Trucksaess, Arno ^{[17
]}

Van Bortel, Luc ^{[18
]}

Weber, Thomas ^{[19
]}

Yamashina, Akira ^{[20
]}

Zimlichman, Reuven ^{[21
,22
]}

Boutouyrie, Pierre ^{[23
,24
]}

Cockcroft, John ^{[25
]}

O'Rourke, Michael ^{[26
]}

Park, Jeong Bae ^{[27
]}

Schillaci, Giuseppe ^{[28
,29
]}

Sillesen, Henrik ^{[30
]}

Townsend, Raymond R. ^{[31
]}

机构：

[1] Univ Athens, Sch Med, Hippokrat Hosp, Peripheral Vessels Unit,Dept Cardiol 1, GR-11527 Athens, Greece

[2] Dupuytren Univ Hosp, Dept Cardiol, Limoges, France

[3] Univ Hosp Graz, Dept Angiol, A-8036 Graz, Austria

[4] Charles Univ Prague, Fac Med 1, Dept Cardiol & Angiol, Prague, Czech Republic

[5] Karolinska Univ Hosp, Dept Med, Cardiol Unit, S-17176 Stockholm, Sweden

[6] Osped Cisanello, Cardiothorac & Vasc Dept, Cardiac Catheterizat Lab, I-56124 Pisa, Italy

[7] Osped San Giovanni Bellinzona, Div Vasc Med, CH-6500 Bellinzona, Switzerland

[8] Charite Univ Med Berlin CBF, Dept Cardiol, D-12203 Berlin, Germany

[9] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Serv Pharmacol, F-75015 Paris, France

[10] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, INSERM,U970, F-75015 Paris, France

[11] Univ Athens, Sch Med, Attikon Univ Hosp, Dept Cardiol 2, GR-11527 Athens, Greece

[12] UCL, Sch Med, Dept Clin Biochem, London NW3 2QG, England

[13] Univ Ioannina, Sch Med, Dept Cardiol 2, GR-45110 Ioannina, Greece

[14] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Hypertens Unit, Athens, Greece

[15] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Internal & Propedeut Med 1, Cardiovasc Res Lab, Athens, Greece

[16] Univ Brescia, Dept Clin & Expt Sci, Med Clin, Brescia, Italy

[17] Univ Basel, Div Sports & Exercise Med, Dept Sport Exercise & Hlth, CH-4052 Basel, Switzerland

[18] Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium

[19] Klinikum Wels Grieskirchen, Dept Cardiol, Wels, Austria

[20] Tokyo Med Univ, Dept Cardiol, Tokyo 1600023, Japan

[21] Tel Aviv Univ, E Wolfson Med Ctr, IL-58100 Holon, Israel

[22] Tel Aviv Univ, E Wolfson Med Ctr, Sackler Fac Med, Hypertens Inst,Brunner Inst Cardiovasc Res, IL-58100 Holon, Israel

[23] Univ Paris 05, AP HP, Dept Pharmacol, F-75015 Paris, France

[24] Univ Paris 05, AP HP, INSERM, U970, F-75015 Paris, France

[25] Wales Heart Res Inst, Dept Cardiol, Cardiff CF14 4XN, S Glam, Wales

[26] Univ New S Wales, Victor Chang Cardiac Res Inst, St Vincents Clin, Sydney, NSW, Australia

[27] Dankook Univ, Coll Med, Cheil Gen Hosp, Dept Med Cardiol, Seoul 100380, South Korea

[28] Univ Perugia, Dept Med, Unit Internal Med, Terni, Italy

[29] Terni Univ Hosp, Terni, Italy

[30] Univ Copenhagen, Rigshosp, Dept Vasc Surg, DK-1168 Copenhagen, Denmark

[31] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

ATHEROSCLEROSIS | 2015年 / 241卷 / 02期

关键词：

Vascular biomarkers; Carotid ultrasonography; Ankle-brachial index; Arterial stiffness; Central haemodynamics; Wave reflections; Endothelial function; Circulating biomarkers; INTIMA-MEDIA THICKNESS; PULSE-WAVE VELOCITY; ANKLE-BRACHIAL INDEX; CENTRAL BLOOD-PRESSURE; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; ALL-CAUSE MORTALITY; CARDIOVASCULAR RISK PREDICTION; HIGH-DENSITY-LIPOPROTEIN; LEFT-VENTRICULAR HYPERTROPHY;

D O I：

10.1016/j.atherosclerosis.2015.05.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required. (C) 2015 The Authors. Published by Elsevier Ireland Ltd.

引用

页码：507 / 532

页数：26

共 33 条

[31] Primary prevention of ischemic stroke - A guideline from the American heart Association/American stroke association stroke council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Goldstein, Larry B.
Adams, Robert
Alberts, Mark J.
Appel, Lawrence J.
Brass, Lawrence M.
Bushnell, Cheryl D.
Culebras, Antonio
DeGraba, Thomas J.
Gorelick, Philip B.
Guyton, John R.
Hart, Robert G.
Howard, George
Kelly-Hayes, Margaret
Nixon, J. V.
Sacco, Ralph L.
CIRCULATION, 2006, 113 (24) : E873 - E923
[32] Association(EHRA) (Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Authors/Task Force Members: Michae Glkson *(Chairperson) ( srael) Prevention and Rehabilitation Section of the European Association of Preventive Je s CosedNielsen*(Ch i pers n) (D nmark) M d Bri Kronb r (Task Forc Cardiology. Translation of the document prepared by the Czech Society of Cardiology)
Tuka, Vladimir
Sovova, Eliska
Pudil, Radek
Skalicka, Hana
COR ET VASA, 2023, 65 : 5 - 33
[33] Primary prevention of ischemic stroke - A guideline from the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group - The American Academy of Neurology affirms the value of this guideline.
Goldstein, Larry B.
Adams, Robert
Alberts, Mark J.
Appel, Lawrence J.
Brass, Lawrence M.
Bushnell, Cheryl D.
Culebras, Antonio
DeGraba, Thomas J.
Gorelick, Philip B.
Guyton, John R.
Hart, Robert G.
Howard, George
Kelly-Hayes, Margaret
Nixon, J. V.
Sacco, Ralph L.
STROKE, 2006, 37 (06) : 1583 - 1633

← 1 2 3 4 →